Syremis Therapeutics

Executive Summary

Syremis Therapeutics is a privately held, preclinical-stage biotechnology company pioneering precision-targeted small-molecule therapies for central nervous system (CNS) disorders. Founded in 2020 and headquartered in Boston, the company leverages a deep understanding of neural circuit dysfunction to develop novel treatments for neuropsychiatric and neurodegenerative diseases. With $165 million in total funding, Syremis aims to address the significant unmet need in CNS drug development by improving efficacy and tolerability over existing standards of care. The company's platform focuses on modulating specific pathways implicated in disorders such as depression, anxiety, and Parkinson's disease, potentially offering differentiated mechanisms that could overcome the high attrition rates typical of CNS programs. As a preclinical entity, Syremis has not yet advanced a candidate into clinical trials, but its substantial funding base and scientific approach position it for potential value-inflection events as it moves toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead program60% success
• Q4 2026Presentation of preclinical data at major neuroscience conference80% success
• TBDPartnership or licensing deal for a non-core asset40% success